316 related articles for article (PubMed ID: 29931499)
1. Metastatic gynecologic malignancies: advances in treatment and management.
Chan JK; Chow S; Bhowmik S; Mann A; Kapp DS; Coleman RL
Clin Exp Metastasis; 2018 Aug; 35(5-6):521-533. PubMed ID: 29931499
[TBL] [Abstract][Full Text] [Related]
2. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
3. An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group.
Shimada M; Yoshihara K; Tanigawa T; Nomura H; Hamanishi J; Fujiwara S; Tanabe H; Kajiyama H; Mandai M; Aoki D; Enomoto T; Okamoto A
J Gynecol Oncol; 2023 May; 34(3):e62. PubMed ID: 37116954
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
Crafton SM; Bixel K; Hays JL
Gynecol Oncol; 2016 Sep; 142(3):588-96. PubMed ID: 27168003
[TBL] [Abstract][Full Text] [Related]
5. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
[TBL] [Abstract][Full Text] [Related]
6. New and Novel Therapies for Gynecologic Cancers.
Richardson DL
Semin Oncol Nurs; 2019 Apr; 35(2):217-219. PubMed ID: 30876683
[TBL] [Abstract][Full Text] [Related]
7. Major clinical research advances in gynecologic cancer in 2018.
Kim M; Suh DH; Lee KH; Eom KY; Toftdahl NG; Mirza MR; Kim JW
J Gynecol Oncol; 2019 Mar; 30(2):e18. PubMed ID: 30806045
[TBL] [Abstract][Full Text] [Related]
8. Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
Pan K; Gong J; Huynh K; Cristea M
Target Oncol; 2019 Jun; 14(3):269-283. PubMed ID: 31069647
[TBL] [Abstract][Full Text] [Related]
9. Genomic-Based Therapy of Gynecologic Malignancies.
Markman M
Acta Med Acad; 2019 Apr; 48(1):84-89. PubMed ID: 31264436
[TBL] [Abstract][Full Text] [Related]
10. Major clinical research advances in gynecologic cancer in 2017.
Suh DH; Kim M; Lee KH; Eom KY; Kjeldsen MK; Mirza MR; Kim JW
J Gynecol Oncol; 2018 Mar; 29(2):e31. PubMed ID: 29468855
[TBL] [Abstract][Full Text] [Related]
11. Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3.
Lee JY; Lee YY; Park JY; Shim SH; Kim SI; Kong TW; Lim CK; Cho HW; Suh DH
J Gynecol Oncol; 2023 Mar; 34(2):e51. PubMed ID: 36890294
[TBL] [Abstract][Full Text] [Related]
12. Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.
Wolford JE; Ferrigni E; Margul D; Herzog TJ
Curr Oncol Rep; 2022 Jul; 24(7):889-904. PubMed ID: 35347591
[TBL] [Abstract][Full Text] [Related]
13. Major clinical research advances in gynecologic cancer in 2014.
Suh DH; Lee KH; Kim K; Kang S; Kim JW
J Gynecol Oncol; 2015 Apr; 26(2):156-67. PubMed ID: 25872896
[TBL] [Abstract][Full Text] [Related]
14. Updates in the Use of Targeted Therapies for Gynecologic Cancers.
Cantillo E; Blanc-Durand F; Leary A; Slomovitz BM; Fuh K; Washington C
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438582. PubMed ID: 38788185
[TBL] [Abstract][Full Text] [Related]
15. Major clinical research advances in gynecologic cancer in 2019.
Kim M; Suh DH; Lee KH; Eom KY; Lee JY; Lee YY; Hansen HF; Mirza MR; Kim JW
J Gynecol Oncol; 2020 May; 31(3):e48. PubMed ID: 32319232
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
17. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
18. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Markman M
Womens Health (Lond); 2018; 14():1745505717750694. PubMed ID: 29313444
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitors in Epithelial Ovarian Cancer.
Taylor KN; Eskander RN
Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
[TBL] [Abstract][Full Text] [Related]
20. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
Kristeleit RS; Miller RE; Kohn EC
Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]